Sildenafil for the Treatment of Alzheimer’s Disease: A Systematic Review

Nitric oxide/cyclic guanosine monophosphate (cGMP) signaling is compromised in Alzheimer’s disease (AD), and phosphodiesterase 5 (PDE5), which degrades cGMP, is upregulated. Sildenafil inhibits PDE5 and increases cGMP levels. Integrating previous findings, we determine that most doses of sildenafil...

Descripción completa

Detalles Bibliográficos
Autor principal: Sanders, Owen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242821/
https://www.ncbi.nlm.nih.gov/pubmed/32467879
http://dx.doi.org/10.3233/ADR-200166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242821/
https://www.ncbi.nlm.nih.gov/pubmed/32467879
http://dx.doi.org/10.3233/ADR-200166

Ejemplares similares